Pazopanib

Pazopanib. It is a tyrosine kinase inhibitor developed by GlaxoSmithKline and approved for medical use by regulatory bodies including the Food and Drug Administration and the European Medicines Agency. This oral medication is primarily indicated for the treatment of advanced renal cell carcinoma and certain types of soft tissue sarcoma. Its mechanism of action involves the targeted inhibition of specific vascular endothelial growth factor receptors and other kinases involved in tumor growth and angiogenesis.

Medical uses

Pazopanib is indicated for the treatment of advanced renal cell carcinoma, having demonstrated efficacy in pivotal trials such as the COMPARZ study which compared it to sunitinib. It is also approved for the treatment of advanced soft tissue sarcoma in patients who have received prior chemotherapy, based on results from the PALETTE trial. The National Comprehensive Cancer Network guidelines include pazopanib as a recommended therapeutic option for these malignancies. Its use is typically reserved for metastatic or advanced disease states where surgical intervention is not feasible.

Adverse effects

Common adverse effects associated with pazopanib include hypertension, diarrhea, nausea, fatigue, and changes in hair color. More serious potential complications involve hepatotoxicity, which necessitates regular monitoring of liver function tests, and QT interval prolongation. Significant cardiotoxicity, including congestive heart failure and myocardial infarction, has been reported in post-marketing surveillance by the Food and Drug Administration. Other risks include arterial thromboembolic events, gastrointestinal perforation, and posterior reversible encephalopathy syndrome.

Pharmacology

Pazopanib functions as a potent multi-target tyrosine kinase inhibitor, selectively blocking intracellular signaling by inhibiting vascular endothelial growth factor receptor-1, -2, and -3, platelet-derived growth factor receptor-α and -β, and fibroblast growth factor receptor-1 and -3. This inhibition disrupts key pathways involved in angiogenesis and tumor cell proliferation. The drug is metabolized primarily in the liver by the cytochrome P450 enzyme CYP3A4, and its pharmacokinetics are significantly affected by concomitant administration of strong CYP3A4 inducers or inhibitors like rifampin or ketoconazole.

History

Pazopanib was discovered through research efforts at GlaxoSmithKline and received its initial approval from the Food and Drug Administration for renal cell carcinoma in October 2009. Subsequent approval for soft tissue sarcoma was granted in April 2012 following the positive results of the phase III PALETTE trial. The development and clinical trials of pazopanib were part of a broader wave of targeted therapies emerging in oncology during the early 21st century. Its regulatory review and post-marketing commitments have been overseen by agencies including the European Medicines Agency and the Pharmaceuticals and Medical Devices Agency in Japan.

Society and culture

Pazopanib is marketed under the brand name Votrient by Novartis, which acquired the oncology portfolio from GlaxoSmithKline. The cost of treatment has been a subject of discussion within healthcare systems, including the National Health Service in the United Kingdom. Its role in therapy is often discussed in the context of value-based cancer care by organizations like the American Society of Clinical Oncology. The drug has been included in treatment guidelines published by the European Society for Medical Oncology and is a subject of ongoing clinical research in other tumor types.

Category:Antineoplastic drugs Category:Tyrosine kinase inhibitors Category:GlaxoSmithKline